Breast Cancer Clinical Trials

Showing 3261-3280 of 5,597 trials

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

NCT04047758

Pfizer's innovative drug palbociclib (trade name: Ibrance®) got China National Drug Administration (CNDA) approval on July 31, 2018. Palbociclib combined with an aromatase inhibitor can be used to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer or metastatic breast cancer. This brings more treatment options for hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer. How to scientifically evaluate the efficacy, tolerability, and safety of palbociclib combined with an aromatase inhibitor and to establish a more suitable treatment strategy for Chinese patients is one of the questions that need to be answered in clinical practice. This multi-center parallel-group randomized controlled trial will address on this issue.

Breast Cancer

Shengjing Hospital420 participantsStarted Sep 2019

Shenyang, Liaoning, China • Shenyang, Liaoning, China • Shenyang, Liaoning, China

RECRUITINGNA

Breast Mesh Used in Two-staged Breast Reconstruction

NCT04967976

This is the first prospective randomized and controlled study on the efficacy and safety of TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of capsular contraction, improve the efficiency of expansion and provide better aesthetic result.

Breast CancerRadiationBreast Reconstruction+1 more

Tianjin Medical University Cancer Institute and Hospital300 participantsStarted Aug 2021

Houston, Texas, United States • Lanzhou, Gansu, China • Ch’ang-ch’un, Jilin, China +3 more locations

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Breast Mesh Used in Two-staged Breast Reconstruction

Related Searches

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Diet and Physical Activity Changes Among Latina Breast Cancer Survivors

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Optoacoustic Images Versus Imagio® Ultrasound

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics

Assessment of Health Related Quality of Life in Women Who Underwent Breast Reconstruction After Radical Surgery

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Circulating Fetal Cells and Breast Cancer

Pilates and Dance to Breast Cancer Patients Undergoing Treatment

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer